IRCT20170225032759N3已完成未知
Comparative bioequivalency study (pharmacokinetics- pharmacodynamics) of Variopeptyl® 11.25 mg and Diphereline® 11.25 mg in Patients with non-metastatic or metastatic prostate cancer Volunteers
Varian Pharmed Co0 个研究点目标入组 80 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 50 years 至 90 years（—）
- 性别
- Male
入选标准
- •Men between the ages of 50 and 90
- •patient with non-metastatic or metastatic prostate cancer whose disease has been diagnosed based on examination and paraclinical procedures.
- •Without cardiovascular, cerebral, renal and liver problems.
- •No history of hormone use, immunosuppressive drugs in the last 2 months
- •No immune system diseases such as AIDS and MS
- •Able and willing to sign informed consent form
排除标准
- •Sensitivity to drugs, especially GnRH-A
- •Previous history of chemotherapy
- •Other diseases
研究者
相似试验
已完成
1 期
Clinical Trial to Evaluate the Pharmacokinetic Characteristics of DW5221 and DW5221-RApetite StimulantsNCT06147908Daewon Pharmaceutical Co., Ltd.54
未知
1 期
DMB-3111 phase IHealthy volunteersJPRN-jRCT2080222436Meiji Seika Pharma Co., Ltd.70
已完成
1 期
A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Siklos® in Healthy VolunteersHealthy VolunteersNCT05025072Theravia28
暂停
不适用
Bioequivalence Study Comparing Generic to Reference Liposome-Encapsulated Doxorubicin HydrochlorideCTRI/2019/05/019051Aine Cunningham
已完成
不适用
Bioequivalence (BE) Study of a New Branded Generic of Moxifloxacin TabletsMoxifloxacin could potentially cause nausea,diarrhea,headache,vomiting,dizziness,nervousness,agitation and nightmares. As for the safety of the formulation,no adverse event was reported based oMoxifloxacinbioequivalencepharmacokineticsTCTR20201109001/A30